STAT+

First Opinion Kendalle Burlin O’Connell

STAT Plus: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma

Business Mario Aguilar and Timmy Broderick

STAT Plus: Apple will offer millions of AirPod users a hearing aid. Can it convince them to use it?

Politics Rachel Cohrs Zhang

STAT Plus: Key Senate Republican throws cold water on Affordable Care Act repeal, site-neutral payment policy

Health tech Brittany Trang

STAT Plus: FDA commissioner: Health systems have to ‘step up’ on AI regulation or will ‘end up holding the bag’

Pharmalot Ed Silverman

STAT Plus: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams

Biotech Brittany Trang

STAT Plus: ‘Sarepta’s like a curse on me’: FDA commissioner dismisses controversy over Elevidys

Health tech Brittany Trang

STAT Plus: Q&A: For this South Dakota health system, leaning into telehealth means learning ‘webside’ manner

Politics Rachel Cohrs Zhang

STAT Plus: How hospitals could make money off of Kamala Harris’ medical debt relief plan

Biotech Jonathan Wosen

STAT Plus: After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives

Insurance Bob Herman

STAT Plus: Elevance buys IU Health’s insurance company

Biotech Elaine Chen

STAT Plus: Novo Nordisk’s amylin pill leads to substantial weight loss in early study

Pharmalot Ed Silverman

STAT Plus: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries

Biotech Adam Feuerstein

STAT Plus: Viridian drug achieves study goals as treatment for thyroid eye disease

Biotech Adam Feuerstein

STAT Plus: Roivant acquires drug for pulmonary hypertension from Bayer

Exclusive Matthew Herper

STAT Plus: Former Verily executives hatch plan to invest millions in high-tech medical data

Politics John Wilkerson

STAT Plus: House passes bill that targets China biotechs

Health Care Inc. Bob Herman

STAT Plus: How powerful hospitals helped take R1 RCM private

Biotech Adam Feuerstein

STAT Plus: Merck executive plays down impact of new lung cancer drug data on Keytruda

Biotech Allison DeAngelis

STAT Plus: RayzeBio, Dice alums raise $370 million for new autoimmune startup

Health tech Mario Aguilar

STAT Plus: Highmark reboots coverage of digital treatments, raising hope among DTx companies

Biotech Angus Chen

STAT Plus: Relay discloses encouraging results for experimental breast cancer treatment

Biotech Matthew Herper

STAT Plus: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights

Biotech Jonathan Wosen and Adam Feuerstein

STAT Plus: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial

Hospitals Bob Herman

STAT Plus: Ascension, other hospitals played active roles to take medical billing company R1 RCM private

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA inspections, Lilly insulin trial results, and more

Biotech Adam Feuerstein

STAT Plus: Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more

Adam's Take Adam Feuerstein

STAT Plus: Alnylam versus BridgeBio: The ATTR-CM debate